Published on in Vol 11, No 10 (2022): October
Preprints (earlier versions) of this paper are
available at
https://preprints.jmir.org/preprint/42585, first published
.

Journals
- Corneli A, Perry B, Des Marais A, Choi Y, Chen H, Lilly R, Ayers D, Bennett J, Kestner L, Meade C, Sachdeva N, McKellar M. Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation. Harm Reduction Journal 2022;19(1) View
- Khati A, Copenhaver M, Xu R, Altice F, Wickersham J, Gautam K, Paudel K, Shrestha R. Oral pre-exposure prophylaxis (PrEP) receipt and persistence among opioid-dependent people who inject drugs initiating PrEP for HIV prevention. Journal of Substance Use and Addiction Treatment 2025;173:209693 View
- Sullivan M, Davis M, O’Cleirigh C, Batchelder A. PrEP Use Likelihood Among People Who Use Opioid Drugs: Understanding Clinical Correlates Along the Opioid Use Disorder Treatment Cascade. AIDS and Behavior 2025 View
